Compare SNT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNT | IMMP |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 61.4M |
| IPO Year | 2023 | 2012 |
| Metric | SNT | IMMP |
|---|---|---|
| Price | $1.83 | $0.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 23.0K | ★ 389.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.29 |
| 52 Week High | $5.34 | $3.53 |
| Indicator | SNT | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 42.43 |
| Support Level | $1.71 | $0.35 |
| Resistance Level | $2.87 | $0.46 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 40.01 | 16.08 |
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.